199 related articles for article (PubMed ID: 26914831)
1. Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction.
Low SK; Fukunaga K; Takahashi A; Matsuda K; Hongo F; Nakanishi H; Kitamura H; Inoue T; Kato Y; Tomita Y; Fukasawa S; Tanaka T; Nishimura K; Uemura H; Hara I; Fujisawa M; Matsuyama H; Hashine K; Tatsugami K; Enokida H; Kubo M; Miki T; Mushiroda T
PLoS One; 2016; 11(2):e0148177. PubMed ID: 26914831
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype.
Miura Y; Imamura CK; Fukunaga K; Katsuyama Y; Suyama K; Okaneya T; Mushiroda T; Ando Y; Takano T; Tanigawara Y
BMC Cancer; 2014 Dec; 14():964. PubMed ID: 25515134
[TBL] [Abstract][Full Text] [Related]
3. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
Mizuno T; Fukudo M; Terada T; Kamba T; Nakamura E; Ogawa O; Inui K; Katsura T
Drug Metab Pharmacokinet; 2012; 27(6):631-9. PubMed ID: 22673043
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
Kim HR; Park HS; Kwon WS; Lee JH; Tanigawara Y; Lim SM; Kim HS; Shin SJ; Ahn JB; Rha SY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):825-35. PubMed ID: 24013576
[TBL] [Abstract][Full Text] [Related]
5. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma.
Mizuno T; Terada T; Kamba T; Fukudo M; Katsura T; Nakamura E; Ogawa O; Inui K
Ann Oncol; 2010 Jun; 21(6):1382-1383. PubMed ID: 20348146
[No Abstract] [Full Text] [Related]
6. Association of Single Nucleotide Polymorphisms in STAT3, ABCB1, and ABCG2 with Stomatitis in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Analysis in Japanese Patients.
Watanabe A; Yamamoto K; Ioroi T; Hirata S; Harada K; Miyake H; Fujisawa M; Nakagawa T; Yano I; Hirai M
Biol Pharm Bull; 2017; 40(4):458-464. PubMed ID: 28381801
[TBL] [Abstract][Full Text] [Related]
7. The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.
Mizuno T; Fukudo M; Fukuda T; Terada T; Dong M; Kamba T; Yamasaki T; Ogawa O; Katsura T; Inui K; Vinks AA; Matsubara K
Ther Drug Monit; 2014 Jun; 36(3):310-6. PubMed ID: 24825438
[TBL] [Abstract][Full Text] [Related]
8. Severe toxicity induced by accumulation of active sunitinib metabolite in a Japanese patient with renal cell carcinoma: a case report.
Takasaki S; Kikuchi M; Kawasaki Y; Ito A; Arai Y; Yamaguchi H; Mano N
J Med Case Rep; 2017 Feb; 11(1):28. PubMed ID: 28143610
[TBL] [Abstract][Full Text] [Related]
9. Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.
Narjoz C; Cessot A; Thomas-Schoemann A; Golmard JL; Huillard O; Boudou-Rouquette P; Behouche A; Taieb F; Durand JP; Dauphin A; Coriat R; Vidal M; Tod M; Alexandre J; Loriot MA; Goldwasser F; Blanchet B
Invest New Drugs; 2015 Feb; 33(1):257-68. PubMed ID: 25344452
[TBL] [Abstract][Full Text] [Related]
10. Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.
Numakura K; Tsuchiya N; Kagaya H; Takahashi M; Tsuruta H; Inoue T; Narita S; Huang M; Satoh S; Niioka T; Miura M; Habuchi T
Anticancer Drugs; 2017 Jan; 28(1):97-103. PubMed ID: 27564227
[TBL] [Abstract][Full Text] [Related]
11. Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
Chu YH; Li H; Tan HS; Koh V; Lai J; Phyo WM; Choudhury Y; Kanesvaran R; Chau NM; Toh CK; Ng QS; Tan PH; Chowbay B; Tan MH
PLoS One; 2015; 10(8):e0134102. PubMed ID: 26244574
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
13. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B; Lambrechts D; Van Brussel T; Wolter P; Cardinaels N; Joniau S; Lerut E; Karadimou A; Couchy G; Sebe P; Ravaud A; Zerbib M; Caty A; Paridaens R; Schöffski P; Verkarre V; Berger J; Patard JJ; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Oct; 53(10):1413-22. PubMed ID: 24874929
[TBL] [Abstract][Full Text] [Related]
14. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
15. ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib.
Werbrouck E; Bastin J; Lambrechts D; Verbiest A; Van Brussel T; Lerut E; Machiels JP; Verschaeve V; Richard V; Debruyne PR; Decallonne B; Schöffski P; Bechter O; Wolter P; Beuselinck B
Acta Clin Belg; 2019 Jun; 74(3):180-188. PubMed ID: 29792121
[TBL] [Abstract][Full Text] [Related]
16. Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.
Teo YL; Wee HL; Chue XP; Chau NM; Tan MH; Kanesvaran R; Wee HL; Ho HK; Chan A
Pharmacogenomics J; 2016 Feb; 16(1):47-53. PubMed ID: 25778465
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.
Noda S; Otsuji T; Baba M; Yoshida T; Kageyama S; Okamoto K; Okada Y; Kawauchi A; Onishi H; Hira D; Morita SY; Terada T
Clin Genitourin Cancer; 2015 Aug; 13(4):350-358. PubMed ID: 25701374
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma.
Kato R; Kato Y; Matsuura T; Kanehira M; Takata R; Obara W
BMC Cancer; 2017 Mar; 17(1):214. PubMed ID: 28335742
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.
Kim HS; Hong MH; Kim K; Shin SJ; Ahn JB; Jeung HC; Chung HC; Koh Y; Lee SH; Bang YJ; Rha SY
Oncology; 2011; 80(5-6):395-405. PubMed ID: 21829041
[TBL] [Abstract][Full Text] [Related]
20. Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma.
Kato H; Sassa N; Miyazaki M; Takeuchi M; Asai M; Iwai A; Noda Y; Gotoh M; Yamada K
Cancer Chemother Pharmacol; 2016 Oct; 78(4):855-62. PubMed ID: 27586968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
